AjeetGajraMDFACP

Oncology • East Syracuse, NY

Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative, Thoracic Cancer

Chief Scientific Officer, HOACNY Sr Medical Consultant, Cardinal Health

Join to view full profile

Dr. Gajra is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gajra's full profile

Already have an account?

Office
5008 Brittonfield Pkwy
East Syracuse, NY 13057
Phone+1 315-472-7504

Fax+1 315-634-5168
Is this information wrong?

Summary

I am a medical oncologist with board certifications in Medical Oncology, Hematology, Palliative Medicine and Internal Medicine. My goal in the clinic is twofold:
First, to provide compassionate care to patients with cancer and blood disorders. As a life long clinical researcher, I lead the clinical research within our practice and strive to bring cancer clinical trials to our patients and community here in the Syracuse area.
My clinical areas of interest are: Thoracic (Lung ca, esophageal ca), Head & Neck, GU (prostate, kidney and bladder cancers) and Geriatric oncology.
It is my firm belief that everyone deserves the same respect and compassion as we expect for ourselves and our families.

Education & Training

SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1996 - 1998
Maulana Azad Medical CollegeClass of 1993

Certifications & Licensure

NY State Medical License 2006 - 2025
IN State Medical License 1998 - 2023
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2012
Anita Award for compassionate care Hospice of Central New York
Inducted Alpha Omega Alpha

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Start of enrollment: 2008 Mar 01
Completed
Phase 2
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2008 Apr 15
Completed
Phase 2
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2010 Feb 01
Terminated
Phase 3
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects Start of enrollment: 2011 Jul 01
Terminated
Phase 2
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
Active, not recruiting
Phase 2
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Start of enrollment: 2022 Jul 29
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

HSR24-172: Comparing Apples to Apples in Uterine Cancer: Racial Disparity and Propensity Score Matching.
Alexandrina Balanean, Yolaine Jeune-Smith, Parisa Asgarisabet, Camryn Craig, Harlen Hays, JaLyna Laney, Bruce Feinberg, Ajeet Gajra> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
1 citations
Oncologist Perceptions of Racial Disparity, Racial Anxiety, and Unconscious Bias in Clinical Interactions, Treatment, and Outcomes.
Alexandrina Balanean, Emily Bland, Ajeet Gajra, Yolaine Jeune-Smith, Andrew J Klink, Harlen Hays, Bruce A Feinberg> ;Journal of the National Comprehensive Cancer Network. 2024 Feb 27
Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946].
Klink, A., Knoth, R., Marshall, L., Hou, Y., McBride, A., Copher, R., Gajra, A.> ;Leukemia Research. 2024 Jan 1
Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
Kristin M Zimmerman Savill, Jasmina Ivanova, Parisa Asgarisabet, Angelica Falkenstein, Alexandrina Balanean, Alexander Niyazov, Joanne C Ryan, Jonathan Kish, Ajeet Gaj...> ;The Oncologist. 2023 May 8
Reducing Avoidable Emergency Visits and Hospitalizations With Patient Risk-Based Prescriptive Analytics: A Quality Improvement Project at an Oncology Care Model Practice.
Ajeet Gajra, Yolaine Jeune-Smith, Alexandrina Balanean, Kelly A Miller, Danielle Bergman, John Showalter, Ray Page> ;JCO Oncology Practice. 2023 May 1
Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.
Andrew J Klink, Ajeet Gajra, Russell L Knoth, Landon Marshall, Ying Hou, Ali McBride, Ronda Copher> ;Leukemia Research. 2022 Nov 1
1 citations
Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
Andrew J Klink, Abhishek Kavati, Awa Gassama, Tom Kozlek, Ajeet Gajra, Ruth Antoine> ;Targeted Oncology. 2022 Sep 1
1 citations
Older Patients with Lung Cancer: a Summary of Seminal Contributions to Optimal Patient Care.
Alina Basnet, Asrar Alahmadi, Ajeet Gajra> ;Current Oncology Reports. 2022 Nov 1
17 citations
The Use and Knowledge of Validated Geriatric Assessment Instruments Among US Community Oncologists.
Ajeet Gajra, Yolaine Jeune-Smith, Stephanie Fortier, Bruce Feinberg, Eli Phillips Jr, Alexandrina Balanean, Heidi D Klepin> ;JCO Oncology Practice. 2022 Jul 1
24 citations
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
Ajeet Gajra, Abigail Zalenski, Aishwarya Sannareddy, Yolaine Jeune-Smith, Kandice Kapinos, Ankit Kansagra> ;Pharmaceutical Medicine. 2022 Jun 1
2 citations
Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Andrew J Klink, Abhishek Kavati, Awa T Gassama, Tom Kozlek, Ajeet Gajra, Ruth Antoine> ;Targeted Oncology. 2022 May 1
Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers.
Daneng Li, Can-Lan Sun, Rebecca Allen, Christiana J Crook, Abrahm Levi, Richard Ballena, Heidi D Klepin, Rawad Elias, Supriya G Mohile, William P Tew, Cynthia Owusu, H...> ;The Oncologist. 2022 Feb 3
1 citations
Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Larg...
Jamile Shammo, Ajeet Gajra, Yogesh Patel, Ioannis Tomazos, Jonathan Kish, Anita Hill, J Rafael Sierra, David Araten> ;Journal of Blood Medicine. 2022 Jan 1
Heterogeneous Versus Homogeneous Radiation Dose Calculations of Twice-Daily Fractionation in Small Cell Lung Carcinoma.
Ryan Thibodeau, Hsin K Li, Sean Tanny, Ajeet Gajra, Jeffrey Bogart> ;Cureus. 2021 Dec 1
16 citations
Impact of social determinants of health on cancer care: a survey of community oncologists.
Marjorie E Zettler, Bruce A. Feinberg, Yolaine Jeune-Smith, Ajeet Gajra> ;BMJ Open. 2021 Oct 6
3 citations
Impact of Augmented Intelligence on Utilization of Palliative Care Services in a Real-World Oncology Setting.
Ajeet Gajra, Marjorie E Zettler, Kelly A Miller, John Frownfelter, John Showalter, Amy W. Valley, Sanya Sharma, Shreenath Sridharan, Jonathan Kish, Sibel Blau> ;JCO Oncology Practice. 2021 Sep 10
Biosimilars And Follow-On Products.
Bruce Feinberg, Ajeet Gajra, Sonia Oskouei> ;Health Affairs. 2021 Sep 1
4 citations
Augmented intelligence to predict 30-day mortality in patients with cancer.
Ajeet Gajra, Marjorie E Zettler, Kelly A Miller, Sibel Blau, Swetha S Venkateshwaran, Shreenath Sridharan, John Showalter, Amy W. Valley, John Frownfelter> ;Future Oncology. 2021 Jun 30
3 citations
Expanded Access and Right To Try Requests: The Community Oncologist's Experience.
Marjorie E Zettler, Yolaine Jeune-Smith, Bruce A. Feinberg, Eli G. Phillips, Ajeet Gajra> ;JCO Oncology Practice. 2021 Apr 22
10 citations
Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy
Heidi D. Klepin, Can-Lan Sun, David D. Smith, Rawad Elias, Kelly M. Trevino, Ashley Leak Bryant, Daneng Li, Christian J. Nelson, William P. Tew, Supriya G. Mohile, Aje...> ;JCO Oncology Practice. 2021 Apr 21
12 citations
Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
Bruce A. Feinberg, Marjorie E Zettler, Andrew J Klink, Choo Hyung Lee, Ajeet Gajra, Jonathan Kish> ;JAMA Network Open. 2021 Feb 1
4 citations
nab -Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis.
Corey J. Langer, Ajeet Gajra, Cesare Gridelli, Kartik Konduri, Daniel Morgensztern, David R. Spigel, Denis Talbot, Michael Thomas, Jared Weiss, Richard Pilot, Rafia Bh...> ;Frontiers in Oncology. 2021 Jan 26
2 citations
Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment.
Bruce Feinberg, Skyler Hime, Jeff Wojtynek, Igoni Dokubo, Ajeet Gajra, Yolaine Smith, Jonathan Kish> ;Future Oncology. 2020 Sep 21
50 citations
Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Bruce A. Feinberg, Ajeet Gajra, Marjorie E Zettler, Todd D. Phillips, Eli G. Phillips, Jonathan Kish> ;Value in Health. 2020 Oct 1
10 citations
Neurological adverse events following CAR T-cell therapy: a real-world analysis.
Ajeet Gajra, Marjorie E Zettler, Eli G. Phillips, Andrew J Klink, Jonathan Kish, Stephanie Fortier, Sonam Mehta, Bruce A. Feinberg> ;Immunotherapy. 2020 Aug 18
Join now to see all

Abstracts/Posters

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World
Ajeet Gajra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age _65 Years
Ajeet Gajra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019